This whitepaper describes three scenarios that clearly demonstrate the value TruScan brings to pharmaceutical manufacturing facilities and the underlying benefits of implementing TruScan that make such extensive savings possible.
Each case study provides an in-depth examination of the deployments of TruScan and concludes with a detailed assessment of the financial yield, from payback through ongoing cost-benefit analysis.
The facilities in all three cases were able to implement TruScan and then recover the initial investment and startup costs quickly—all broke even within 12 months. Projected four-year returns on investment ranged from 268% to 339%, and cost savings ranged from ~US$600,000 to >$800,000.
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.